Exchange: STO Sector: Healthcare Industry: Biotechnology
1.53% SEK29.95
America/New_York / 17 mai 2024 @ 11:29
FUNDAMENTALS | |
---|---|
MarketCap: | 1 970.84 mill |
EPS: | -5.08 |
P/E: | -5.90 |
Earnings Date: | Apr 24, 2024 |
SharesOutstanding: | 65.80 mill |
Avg Daily Volume: | 0.0746 mill |
RATING 2024-05-17 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Sell | |
P/E: | Sell | |
Price To Book: | Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -5.90 | sector: PE 19.76 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -5.90 | industry: PE 491.84 |
DISCOUNTED CASH FLOW VALUE |
---|
SEK-20.81 (-169.48%) SEK-50.76 |
Date: 2024-05-18 |
Expected Trading Range (DAY) |
---|
SEK 28.91 - 30.99 ( +/- 3.48%) |
ATR Model: 14 days |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | SEK29.95 (1.53% ) |
Volume | 0.0732 mill |
Avg. Vol. | 0.0746 mill |
% of Avg. Vol | 98.12 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.